YEAR                       EVENTS
 1971 - The Company was incorporated on 15th January, in Madhya
 Pradesh.
        The Company is the manufacturer of Vitamin C Sodium
 ascorbate,
        calcium ascarbate, sorbitol 100%, sorbitol 60% and other
 drugs,
        pharmaceuticals & chemicals.
 
 1973 - The name of the Company was originally Suneeta Vitamins &
        Chemicals, Ltd.  It was changed to Jayant Vitamins, Ltd., on
 28th
        November.
 
 1975 - Steps were taken in December, to double the capacity of
 Vitamin
        `C' from 142.5 tonnes to 300 tonnes per annum.
 
 1977 - 3,60,000 No. of Equity shares taken up by promoters, etc.
 20,000
        Pref. and 5,40,000 No. of equity shares offered at par to the
        public in October 1973.
 
 1978 - 4,50,000 Rights Equity shares issued at par in prop. 1:2
 during
        1978-79.
 
 1985 - The Company commissioned a glucose plant with a capacity of
        33,000 tonnes on 27th March.  The Company's new division
        pharmaceutical `Jwalin Pharmaceuticals' successfully initiated
 
        production and distribution of certain pharmaceutical
        formulations.
 
      - Necessary approvals were received to increase the licensed
        capacity of vitamin `C' from 770 tonnes to 10,770 tonnes per
        annum and that of sorbitol from 8,000 tonnes to 26,000 tonnes
        per annum.
 
      - Licences for other chemicals, bulk drugs such as glucose,
 vitamin
        `E', Mannitol, salbutamol and various formulations were also
        received.
 
 1986 - The company introduced Mannitol IP as an import substitution
        product.  The Capacity of the glucose plant was increased to
        16,500 TPA.
 
      - During the year, the Company increased Mannitol's capacity to
 180
        TPA and that of the tableting section to 56 million tablets
 per
        annum.
 
      - 13,50,00 Rights equity shares issued at par in prop. 1:1.
        Another 67,500 No. of equity shares issued at par to employees
 of
        the Company (all were taken up).
 
 1987 - The Company issued 2,00,000-14% non-convertible debentures of
 Rs
        100 each on private placement basis to UTI, LIC, GIC and its
        subsidiaries.  These debentures are redeemable at 5% premium
        after 7 years from the date of allotment i.e. on 29.6.1995.
 
      - Part `B' if Rs 15 of the face value of each debenture was to
 be
        redeemed at par in three equal annual instalments at the end
 of
        6th, 7th and 8th year respectively from the date of allotment
 of
        debentures.
 
      - 11,07,000 bonus equity shares issued in prop. 2:5.
 
 1988 - 9.5% Pref. shares redeemed on 22.1.1989.  50,000-14% Pref.
 shares
        issued.  These Pref. shares redeemable during 15.6.1996/99.
 
 1989 - During August-September, the Company offered 3,87,450-12.5%
        secured redeemable Convertible debentures of Rs 100 each on
        Rights basis in propn. 1 debenture : 10 equity shares held. 
 (All
        were taken up) Additional 13,573 debentures were allotted to
        retain oversubscription.
 
      - Simultaneously another 19,370 - 12.5% debentures were issued
 to
        employees (including Indian working directors)/workers of the
        company on an equitable basis (none were taken up) 19,000
        debentures out of the employees quota were allotted to SBI
 Mutual
        Fund.
 
      - Consent of the Controller of Capital issues was also received
 to
        issue privately 2,00,000-12.5% partly convertible debentures
 of
        Rs 100 to ICICI/UTI/SBI Mutual Fund.  Out of this 1,44,000
        debentures were allotted till the end of November.
 
      - Rs 20 of the face value of each debenture was automatically
 and
        compulsorily converted into one equity share of Rs 10 each at
 a
        premium of Rs 10 per share on the expiry of 6 months from the
        date of allotment of debentures.
 
      - Rs 30 of the face value of each debenture was to be
 automatically
        and compulsorily converted into one equity shares of Rs 10
 each
        at a premium of Rs 20 per share on the expiry of one year
 from
        the date of allotment of debentures.
 
      - The remaining Rs 50 of the face value of each debenture was to
 be
        redeemed at par at the end of 7th, 8th and 9th year from the
 date
        of allotment of debentures.
 
      - 5,64,023 No. of Equity shares allotted in part conversion of
        debentures (4,20,023 on 26.04.1990.  1,25,000 shares on
 17.5.1990
        and 19,000 shares on 31.5.1990).
 
 1990 - 5,65,034 No. of equity shares allotted in part conversion of
        debentures.
 
 1991 - Production was severely hampered due to the fact that Vitamins
 A 
        and C were brought once again under the purview of Drugs
 (Prices
        Control) Order.
 
      - The delays and related aspects that arise in getting Govt.'s
        sanction to get its selling prices commensurate withcosts, led
 to 
        severe working capital strains resulting in frequent and
        prolonged closures.
 
      - 17,23,037 No. of equity shares allotted (prem. Rs 5 per share)
 in
        part conversion of debs.
 
 1992 - During March-April, the Company issued 15,00,000-15% secured
        partly convertible debentures of Rs 30 each on Rights basis
 in
        the proportion 3 debentures : 10 equity shares held (all were
        taken up).  Additional 2,25,000 debentures were allotted to
        retain oversubscription.  Of these, 1026 debentures are yet to
 be
        allotted.
 
      - Another 75,000-15% partly convertible debentures of Rs 30
 each
        were offered to the employees' on an equitable basis (details
 of
        allotment not known).
 
      - Part `A' of Rs 15 of the face value of each debenture was to
 be
        converted into one equity shares of Rs 10 each at a premium of
 Rs
        5 per share on the expiry of six months from the date of 
        allotment of debentures.
 
 1993 - 26,797 Shares out of above issue allotted.
 
 1994 - 10,00,000 shares allotted to promoters and associates on
 private
        placement basis.
 
 2001 - Crisil has revised its rating in respect of the company's NCDs
 from `D' to
              `NM' (not meaningful).